May 2018 Briefing – Pharmacy
Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for May 2018. This roundup includes the latest...
Postmenopausal Sex Hormone Levels Associated With Later CVD
Higher testosterone/estradiol ratio linked to elevated risk for incident cardiovascular disease
Abortion Not Tied to Significantly Higher Antidepressant Use
Risk factors associated with antidepressant use include previous antianxiety, antipsychotic meds
Knowledge Gaps Found for Non-Drug Therapy in Peds ADHD
Review finds no new guidance on comparative effectiveness of these treatments in children, teens
Studies ID Impact of U.S. Opioid-Related Mortality, Rx Patterns
Burden of deaths up; most patients receiving opioid analgesics use immediate-release formulations
Oral Propranolol Seems Safe for Infantile Hemangioma
Good safety profile for children with infantile hemangioma with no prespecified underlying disease
Galcanezumab Beats Placebo for Episodic Migraine
Treatment with 120- or 240-mg galcanezumab linked to reduction in migraine days versus placebo
ASHP: SVP, Injectable Opioid Shortages Threaten Patient Care
98.4 percent of respondents report moderate, severe shortages of morphine, hydromorphone, fentanyl
No Consistent Cardiovascular Benefit Seen for Supplements
Generally moderate- or low-quality evidence for preventive benefits, no effect, or increased risk
FDA Issues Final Guidance on Inhalational Anthrax
Final guidance designed to assist in development of drugs for prophylaxis of inhalational anthrax
